Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310

Data ReadoutpositiveCTX310Positive

AI Analysis

Summary

New England Journal of Medicine published durability data for CTX310, a CRISPR-Cas9 gene editing therapy targeting ANGPTL3. The publication demonstrates long-term efficacy of the gene editing approach.

Clinical Trial Data

Outcome Details

Durability data for CRISPR-Cas9 gene editing targeting ANGPTL3

Importance:6/10

Sentiment:

0.60

gene-editingCRISPR-Cas9ANGPTL3durabilitypublished-data

Related Companies

$CRSP

Read the original article

Published by New England Journal of Medicine on August 28, 2026 2:30 AM

Read Original